U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details

Xq28 Duplication Syndrome, Int22h1/Int22h2 Mediated

Synonym: Xq28 Int22h-1/Int22h-2 Duplication Syndrome

, MD, , MD, FAAP, FACMG, , MD, PhD, and , PhD, MBA, FACMG.

Author Information and Affiliations

Initial Posting: ; Last Update: September 4, 2025.

Estimated reading time: 32 minutes

Summary

Clinical characteristics.

Clinical features of int22h1/int22h2-mediated Xq28 duplication syndrome in males can include mild-to-moderate developmental delay / intellectual disability, a characteristic behavioral profile (aggression, irritability, ADHD, autism, anxiety, sleep disturbance, and socialization issues), recurrent sinopulmonary infections (e.g., otitis media, sinusitis, recurrent upper respiratory tract infections), atopic conditions (i.e., asthma, allergic rhinitis, and eczema), obesity with or without tall stature, and nonspecific facial dysmorphic features. However, several adult males with this duplication have been reported who have no discernable cognitive or neurobehavioral manifestations, suggesting reduced penetrance with respect to cognition and neurobehaviors. Most heterozygous females are clinically unaffected or have inconspicuous findings. However, some heterozygous females can display a milder phenotype predominantly consisting of mild learning disabilities, inattentive-type childhood ADHD-like manifestations, and nonspecific facial dysmorphic features similar to those seen in affected males.

Diagnosis/testing.

The diagnosis of int22h1/int22h2-mediated Xq28 duplication syndrome is established in hemizygous males or heterozygous females by detection of a 0.5-Mb duplication of the subregion extending from 154.1 Mb to 154.6 Mb within the q28 region of the X chromosome in the reference genome (NCBI Build GRCh37/hg19).

Management.

Treatment of manifestations: Regular exercise and referral for nutritional counseling in those with obesity. Consider conservative treatment with proper sleep hygiene practices for sleep disturbance. Standard treatment for developmental delay / intellectual disability, kyphoscoliosis, recurrent sinopulmonary infections, asthma, allergic rhinitis, eczema, hearing loss, refractive errors / strabismus, undervirilization in males, and congenital heart defects.

Surveillance: At each visit, measure growth / anthropometric parameters; monitor progress along age-expected neurodevelopmental milestones; assess and screen for anxiety, irritability, aggression, self-injurious behaviors, attention deficits, hyperactivity, impulsivity, and sleep disturbances; PT/OT assessment of gross and fine motor skills, mobility, and self-care skills. Annually in childhood and adolescence, reassess special educational needs. At least annually or as clinically indicated, orthopedics follow up; audiology evaluation; ophthalmology evaluation; repeat pulmonary function testing as needed in those with moderate-to-severe asthma; assess response to prescribed medications.

Evaluation of relatives at risk: Targeted duplication analysis of apparently asymptomatic at-risk male and female relatives of an affected individual is appropriate in order to identify as early as possible those who would benefit from early intervention services.

Genetic counseling.

Int22h1/int22h2-mediated Xq28 duplication syndrome is inherited in an X-linked manner. Most affected individuals reported to date exhibit maternal inheritance of the duplication. Paternal inheritance of the duplication has been reported in eight affected individuals. Hemizygous males transmit the int22h1/int22h2-mediated Xq28 duplication to all of their daughters and none of their sons. Heterozygous females have a 50% chance of transmitting the duplication to offspring in each pregnancy. Once the int22h1/int22h2-mediated Xq28 duplication has been identified in an affected family member, prenatal and preimplantation genetic testing for a pregnancy at increased risk are possible.

Diagnosis

For the purposes of this GeneReview, the terms "male" and "female" are narrowly defined as the individual's biological sex at birth as it determines clinical care [Caughey et al 2021].

Suggestive Findings

Int22h1/int22h2-mediated Xq28 duplication syndrome should be considered in males with the following clinical findings and family history:

  • Mild-to-moderate developmental delay and/or intellectual disability
  • Any of the following features presenting in infancy or childhood:
    • Characteristic neurobehavioral profile consisting of aggression and irritability, attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, anxiety, socialization deficits, and sleep disturbances (typically insomnia)
    • Recurrent sinopulmonary infections (including otitis media) with existent atopic conditions (e.g., asthma, allergic rhinitis, eczema)
    • Obesity with or without tall stature
    • Nonspecific but consistent facial features (See Clinical Description and Figure 1A-E.)
Figure 1.

Figure 1.

Facial features of affected males (A-E) and heterozygous females (F-K) with int22h1/int22h2-mediated Xq28 duplication syndrome A and B are brothers, ages 11 and 3 years, respectively.

Int22h1/int22h2-mediated Xq28 duplication syndrome should be considered in females with the following clinical findings:

  • Mild learning disabilities
  • Neurobehavioral manifestations resembling those of the inattentive-type childhood ADHD (impulsivity, inattention, and emotional lability)
  • Mild-to-moderate socialization deficits
  • Nonspecific but consistent facial features (See Clinical Description and Figure 1F-K.)

Family history is consistent with X-linked inheritance (e.g., no male-to-male transmission). Absence of a known family history does not preclude the diagnosis.

Establishing the Diagnosis

Male proband. The diagnosis of int22h1/int22h2-mediated Xq28 duplication syndrome, also referred to as distal Xq28 duplication syndrome, is established in a male proband with suggestive findings by detection of a 0.5-Mb duplication of the subregion extending from 154.1 Mb to 154.6 Mb within the q28 region of the X chromosome in the reference genome (NCBI Build GRCh37/hg19).

Female proband. The diagnosis of int22h1/int22h2-mediated Xq28 duplication syndrome can be established in a female proband with suggestive findings by detection of a 0.5-Mb duplication of the subregion extending from 154.1 Mb to 154.6 Mb within the q28 region of the X chromosome in the reference genome (NCBI Build GRCh37/hg19).

More specifically, the duplicated segment extends from a low copy repeat (LCR) region within intron 22 of F8, also known as intron 22 homologous region 1 (int22h1), to another LCR region located about 0.5 Mb telomeric to the former region and known as intron 22 homologous region 2 (int22h2). This duplication is likely mediated by a nonallelic homologous recombination event between the int22h1 and int22h2 LCR regions.

Note: Multiple reported individuals have duplications nested within or partially overlapping with the typical int22h1/int22h2-mediated 0.5-Mb Xq28 duplication (see Genotype-Phenotype Correlations and Genetically Related Disorders).

Molecular genetic testing approaches can include a combination of chromosomal microarray (see Option 1) and comprehensive genomic testing (exome sequencing, genome sequencing; see Option 2).

Option 1

Chromosomal microarray (CMA) performed most commonly with SNP (single-nucleotide polymorphism) genotyping arrays is capable of detecting the presence of an int22h1/int22h2-mediated Xq28 duplication. However, the ability of the specific array used to size the detected duplication depends largely on the type and probe density of the array itself. The int22h1/int22h2-mediated Xq28 duplication cannot be identified through routine analysis of G-banded chromosomes or other conventional cytogenetic banding techniques.

Note: (1) Most individuals with an int22h1/int22h2-mediated Xq28 duplication can be identified with the current CMA performed routinely for a clinical indication of neurodevelopmental delay and/or intellectual disability. (2) Routine CMA platforms before 2011 did not include coverage for this region and thus could not detect this duplication. Likewise, the earlier BAC (bacterial artificial chromosome)-based arrays were also incapable of detecting this duplication. (3) Metaphase FISH is not reliable for detecting a duplication of this size (i.e., ~0.5 Mb). However, interphase FISH (iFISH) may be used if appropriate control studies are performed. (4) FISH analysis can also be sought to determine whether the duplicated segment may have been inserted elsewhere in the genome (i.e., insertion translocation).

Option 2

Comprehensive genomic testing. Exome sequencing is commonly used and often can detect this duplication if the exome sequencing is accompanied by CNV (copy number variation) analysis, which is not always the case, depending on the clinical lab. Genome sequencing is also possible and is designed to detect these types of chromosomal duplications and deletions. American College of Medical Genetics and Genomics and the American Academy of Pediatrics recommend exome/genome sequencing as first- or second-tier diagnostic testing for children with developmental delay, intellectual disability, and/or multiple congenital anomalies [Manickam et al 2021, Rodan et al 2025].

For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

Table 1.

Genomic Testing Used in Int22h1/Int22h2-Mediated Xq28 Duplication Syndrome

Duplication 1Region Location 2MethodProportion of Pathogenic Duplications Identified by Method
0.5-Mb duplication at Xq28 (hemizygous in males; heterozygous in females)GRCh37/hg19 chrX:154124111-154564398CMA 3100% 4
Genome sequencing>99%
1.

See Molecular Genetics for details of the duplication and genes of interest in this region.

2.

Genomic coordinates represent the minimum duplication size associated with the int22h1/int22h2-mediated Xq28 duplication as designated by ClinGen. Duplication coordinates may vary slightly based on array design used by the testing laboratory. Note that the size of the duplication as calculated from these genomic positions may differ from the expected duplication size due to the presence of segmental duplications near breakpoints.

3.

Chromosomal microarray analysis (CMA) uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications (including int22h1/int22h2). CMA designs in current clinical use target the Xq28 region. The ability to determine the size of the duplication depends on the type of microarray used and the density of probes in the Xq28 region. Note: The int22h1/int22h2-mediated Xq28 duplication may not have been detectable by older oligonucleotide or BAC platforms.

4.

Clinical Characteristics

Clinical Description

Int22h1/int22h2-mediated Xq28 duplication syndrome, also referred to as distal Xq28 duplication syndrome, is commonly characterized by cognitive impairment, neurobehavioral abnormalities, a combination of recurrent sinopulmonary infections (e.g., otitis media, sinusitis, recurrent upper respiratory tract infections) and atopic conditions (i.e., asthma, allergic rhinitis, and eczema), obesity, and nonspecific facial dysmorphic features (see Tables 2 and 3). However, Billes et al [2024] and Levy et al [2024] both reported several adult males with this duplication who had no discernable cognitive or neurobehavioral manifestations, suggesting that this duplication may display reduced penetrance with respect to cognition and neurobehaviors.

Most heterozygous females are clinically unaffected or have inconspicuous abnormalities. However, heterozygous females can display a milder phenotype predominantly consisting of mild learning disabilities, inattentive-type childhood attention-deficit/hyperactivity disorder (ADHD)-like manifestations, and nonspecific facial dysmorphic features similar to those seen in affected males (see Tables 2 and 3).

To date, approximately 73 living individuals (34 males and 39 females) with the typical 0.5-Mb int22h1/int22h2-mediated Xq28 duplication have been identified and reported within the literature. The clinical features discussed below are based on the phenotypic manifestations reported in these individuals [El-Hattab et al 2011, Lannoy et al 2013, Vanmarsenille et al 2014, El-Hattab et al 2015, Ballout et al 2020, Chien et al 2022, Billes et al 2024, Levy et al 2024].

Note: Features of individuals who have nested or elongated versions of the classic duplication are discussed in Genetically Related Disorders.

Males

Table 2.

Int22h1/Int22h2-Mediated Xq28 Duplication Syndrome: Selected Clinical Manifestations in Males

ManifestationMales (n=34) 1Comments
ID or cognitive impairment ~74% 2, 3Language delay is seen in about 20%.
Sinopulmonary issues ~50%May include otitis media, pneumonia, URI, asthma, &/or allergic rhinitis
Atopic disease ~40%
ADHD/ADD 32%
Overweight or obesity 26%
Neurobehavioral/
psychiatric issues
~20%-25%May include anxiety, ASD, socialization deficits, mood disorders (mainly depression or bipolar disorder), psychotic disorders (e.g., schizophrenia), aggression/irritability, self-mutilation, or self-harming behaviors
Sleep disturbance 15%Mainly issues w/sleep maintenance
Tall stature ~12%
Eye anomalies / refractive error RareBoth strabismus & astigmatism have been reported.

ADHD = attention-deficit/hyperactivity disorder; ADD = attention-deficit disorder; ASD = autism spectrum disorder; ID = intellectual disability; URI = upper respiratory infections

1.

One of the recently published reports did not report the frequencies of sleep disturbances, psychiatric disorders, sinopulmonary infections, atopic conditions, and/or anthropometric abnormalities [Levy et al 2024]. Thus, it is likely that the provided percentage estimates for each feature of these phenotypic categories underpredict the true prevalence of such features in affected males.

2.

Intellectual disability could not be assessed in two affected males because they were lost to follow up.

3.

One reported male experienced perinatal hypoxia, which could be a confounding/contributing factor to his intellectual disability [Billes et al 2024].

For a detailed list of manifestations by sex, click here.

Developmental delay / intellectual disability. The vast majority of reported affected males have developmental delay / intellectual disability. Developmental delay (with language delay in about 20%) is most often in the mild-to-moderate range and is usually recognized in early childhood. However, Billes et al [2024] reported four adult males hemizygous for the int22h1/int22h2-mediated Xq28 duplication who had no associated neurocognitive findings. Subsequently Levy et al [2024] described a further three hemizygous males who were seemingly unaffected with respect to cognition and neurobehaviors [Levy et al 2024], suggesting reduced penetrance for neurocognitive manifestations in hemizygous males.

Neurobehavioral/psychiatric abnormalities. A characteristic neurobehavioral profile has been observed, consisting of:

  • Aggression and irritability
  • Attention-deficit/hyperactivity disorder (ADHD)
  • Autism spectrum disorder
  • Anxiety
  • Socialization deficits
  • Sleep disturbances (See Sleep disturbanes below.)

Less common findings may include:

  • Various socialization deficits
  • Mood disorder (mainly depression or bipolar disorder)
  • Motor tics
  • Psychotic disorder, including schizophrenia
  • Obsessive compulsive disorder (OCD)

Recurrent sinopulmonary infections and atopic diseases. Most males with a history of recurrent sinopulmonary infections also had atopic diseases, making this particular combination somewhat a "signature" in affected males.

  • Almost 50% of affected males have a positive history of recurrent sinopulmonary infections including:
    • Otitis media
    • Pneumonia
    • Upper respiratory tract infections
  • Nearly 40% of affected males have a history of atopic diseases, including:
    • Asthma
    • Eczema
    • Allergic rhinitis

Sleep disturbances. Sleep disturbances, observed in about 15% of hemizygous males, are most often characterized as insomnia that involves difficulty remaining asleep (i.e., sleep maintenance).

  • One affected male experienced disrupted sleep maintenance due to nocturnal enuresis at age 16 years.
  • Another reported affected male exhibited difficulty initiating sleep [Ballout et al 2020, Billes et al 2024].

Anthropometric findings

  • Overweight or obesity has been reported in more than one quarter of affected males, with tall stature in about 10%.
  • About 5% of affected males have acquired microcephaly, although one reported male had macrocephaly [Billes et al 2024].

Nonspecific facial dysmorphic features. The most common facial features in affected males are as follows (see Figure 1):

  • Tall forehead (32%)
  • Thick and broad vermilion of the lower lip (~15%)
  • Large ears (~15%)

Other less common facial features include:

  • Sparse scalp hair and sparse eyebrows
  • Long eyelashes
  • Bulbous nose
  • Thin vermilion of the upper lip
  • Elongated and smooth philtrum
  • Micrognathia or retrognathia

Eye anomalies/refractive error are less common; four males have strabismus and three males have astigmatism. Myopia and unilateral ptosis have been reported in one male each [Ballout et al 2020, Billes et al 2024].

Other rarely reported features (either rare manifestations of Xq28 duplication syndrome or rare, unrelated co-occurrences) that have each been described in one or two affected males each [Ballout et al 2020, Billes et al 2024]:

  • Limb and digital anomalies
    • Pes planus
    • Bilateral talipes equinovarus or arthrogryposis
    • Preaxial polydactyly
    • Hip dysplasia
    • Kyphoscoliosis
  • Sensorineural hearing loss
  • Genitourinary malformations
    • Micropenis with hypospadias
    • Cryptorchidism (unilateral or bilateral)
    • Hydronephrosis
    • Duplex kidney
    • Imperforate anus
  • Esophageal atresia with tracheoesophageal fistula, associated with cleft lip and cleft palate (2 males)
  • Minor congenital heart defects, including atrial septal defect, ventricular septal defect, and/or patent ductus arteriosus
  • Axial hypotonia with peripheral hypertonia

Heterozygous Females

As is typical for X-linked disorders, heterozygous females may have no discernable features at all or may have milder and/or fewer features compared to hemizygous males. A small subset of heterozygous females reported to date exhibited findings that almost mirror those seen in affected males [Billes et al 2024].

Table 3.

Int22h1/Int22h2-Mediated Xq28 Duplication Syndrome: Clinical Manifestations in Females

Manifestation 1Females (n=39)Comments
ID or cognitive impairment 11 (28%) 2Language delay has been reported in 3 (~8%).
ADHD/ADD 4 (10%)
Neurobehavioral/
psychiatric issues
Up to 8%May include anxiety, ASD, socialization deficits, mood disorders (mainly depression or bipolar disorder), psychotic disorders (e.g., schizophrenia), aggression/irritability, self-mutilation, or self-harming behaviors
Sleep disturbance 3 (~8%)More commonly issues w/sleep initiation

ADHD = attention-deficit/hyperactivity disorder; ADD = attention-deficit disorder; ASD = autism spectrum disorder; ID = intellectual disability

1.

No heterozygous females have been reported to exhibit either recurrent sinopulmonary infections or atopic disease.

2.

One female was born to a mother taking valproate during pregnancy, which could be a contributing factor for the behavioral and cognitive abnormalities observed in this individual [Billes et al 2024].

Developmental delay / intellectual disability. Fewer than one third of heterozygous females have some degree of intellectual disability, typically in the mild range (if present) and more likely to become apparent in later life. Fewer than 10% of affected females have language delays noted in childhood.

Neurobehavioral/psychiatric abnormalities. A small proportion of heterozygous females have ADHD/ADD, anxiety, socialization deficits, and/or autism. Less common findings may include:

  • Mood disorders (mainly depression or bipolar disorder) (2 females)
  • Self-mutilation or self-harming behaviors (1 female)
  • Aggression and irritability (1 female)

No heterozygous females have been reported to date to have a psychotic disorder.

Sleep disturbances have been reported in ~8% of heterozygous females and are more likely to involve difficulty falling asleep (i.e., sleep initiation), although one reported heterozygous female had interrupted sleep secondary to sleep apnea.

Anthropometric findings. Only one heterozygous female was overweight, and one had microcephaly. Tall stature has not been reported in heterozygous females.

Nonspecific facial dysmorphic features. The most common facial features in heterozygous females are the same as in affected males (see Figure 1):

  • Tall forehead (26%)
  • Thick and broad vermilion of the lower lip (~18%)
  • Large ears (~8%)

Other less common facial features may include:

  • Sparse scalp hair and sparse eyebrows
  • Long eyelashes
  • Thin vermilion of the upper lip
  • Elongated and smooth philtrum
  • Micrognathia or retrognathia

Other rarely reported features (either rare manifestations of Xq28 duplication syndrome or rare, unrelated co-occurrences) that have each been described in one heterozygous female each [Ballout et al 2020, Billes et al 2024]:

  • Sensorineural hearing loss
  • Kyphoscoliosis

X-chromosome inactivation analyses were skewed in ten of 13 heterozygous females, although the skewed inactivation was inconsistent with nearly equal frequencies of inactivation of the normal X chromosome and the X chromosome containing the duplication. Moreover, no association could be appreciated between the X-chromosome inactivation pattern and the corresponding cognitive phenotype in the studied females, with random and skewed inactivation patterns being seen at nearly equal rates in heterozygous females with or without intellectual disability [El-Hattab et al 2015]. Billes et al [2024] evaluated the X-chromosome inactivation in a further four heterozygous females and found similar results, thereby supporting prior observations. However, X-chromosome inactivation analyses have not been performed for all heterozygous females, making it difficult to ascertain whether this conclusion will remain valid.

Genotype-Phenotype Correlations

The int22h1 and int22h2 regions on Xq28 includes several genes: FUNDC2, MTCP1, BRCC3, VBP1, RAB39B, CLIC2, and part of F8. The cognitive and neurobehavioral manifestations in individuals with the duplication syndrome has been hypothesized to be the result of increased dosages of CLIC2 and RAB39B (see Molecular Genetics).

Prevalence

The typical 0.5-Mb int22h1/int22h2-mediated Xq28 duplication has been reported in 73 living individuals (34 males and 39 females) to date [El-Hattab et al 2011, Lannoy et al 2013, Vanmarsenille et al 2014, El-Hattab et al 2015, Ballout et al 2020, Billes et al 2024, Levy et al 2024].

Vanmarsenille et al [2014] estimated its prevalence at 1:1,000 among males with X-linked intellectual disability syndromes. However, in the absence of population-based studies and due to the rarity of the syndrome, this may be an overestimate.

Differential Diagnosis

Because the phenotypic features associated with int22h1/int22h2-mediated Xq28 duplication syndrome are not sufficient on their own to make a diagnosis of the condition, all disorders with intellectual disability without specific distinctive features should be considered in the differential diagnosis. See OMIM Phenotypic Series for genes associated with:

MECP2 duplication syndrome. Several other duplications involving the Xq28 region also result in distinct X-linked intellectual disability syndromes. One notable example is MECP2 duplication syndrome, a severe neurodevelopmental disorder characterized by early-onset hypotonia, feeding difficulty, gastrointestinal abnormalities such as gastroesophageal reflux and constipation, neurodevelopmental delays, severe intellectual disability, progressive spasticity, recurrent respiratory infections, and seizures. MECP2 duplication syndrome is 100% penetrant in affected males. In contrast, heterozygous females with a MECP2 duplication have been reported to be asymptomatic or have a wide range of possible findings, ranging from mild intellectual disability to a severe phenotype similar to that observed in affected males. In addition to the aforementioned core features of the syndrome, autism spectrum disorders, nonspecific neuroradiologic findings on brain MRI, mottled skin, and urogenital anomalies have also been reported in affected males.

The syndrome is caused by duplications ranging from 0.3 to 4 Mb in the Xq28 chromosome region that includes all of MECP2. In contrast, int22h1/int22h2-mediated Xq28 duplication syndrome is caused by 0.5-Mb duplication in the int22h1/int22h2 region of Xq28 that is located telomeric to the MECP2 locus and extends from 154.1 to 154.6 Mb.

Intellectual disability and recurrent infections are common findings in both syndromes, with males being more severely affected than females. However, spasticity has not been reported to date in int22h1/int22h2-mediated Xq28 duplication syndrome, and seizures have only been reported in a single affected individual [Ballout et al 2020]. Hypotonia has been reported in two males with int22h1/int22h2-mediated Xq28 duplication syndrome, one of whom had generalized hypotonia, while the other had axial hypotonia with peripheral hypertonia [Ballout et al 2020, Billes et al 2024].

Management

No clinical practice guidelines for int22h1/int22h2-mediated Xq28 duplication have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.

Although the features of int22h1/int22h2-mediated Xq28 duplication syndrome are typically more pronounced in affected males compared to heterozygous females, affected males and heterozygous females with suggestive clinical findings including neurobehavioral abnormalities and language delays are managed with a similar clinical approach.

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with int22h1/int22h2-mediated Xq28 duplication, the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to diagnosis) are recommended.

Table 4.

Int22h1/Int22h2-Mediated Xq28 Duplication Syndrome: Recommended Evaluations Following Initial Diagnosis

System/ConcernEvaluationComment
Growth/
Anthropometrics
Measurement of weight, length/height, & head circumferenceFor those w/obesity, consider referral to nutritionist & dietician.
Neurodevelopmental milestones & cognition Age-appropriate neurodevelopmental & cognitive assessments
  • Neurodevelopmental milestone assessment should incl motor, cognitive, & speech-language eval.
  • Early identification of neurodevelopmental delays would allow for early intervention.
Neurobehavioral & psychiatric abnormalities Neuropsychiatric evals 1For persons age ≥12 mos, screen for neurobehaviorial concerns such as aggression, irritability, emotional lability, self-mutilation, motor tics, &/or findings suggestive of ASD, based on individual presentation.
Sleep Consider consulting sleep specialist for possible sleep study.
Musculoskeletal Assessment of spine & vertebrae via spinal radiographs to detect features incl abnormal spinal curvature (e.g., kyphoscoliosis)If kyphoscoliosis is identified, consider referral to orthopedist & PT for mgmt.
Allergy/Immunology (for males)Screen for recurrent infections & atopy, 2 esp in affected males.Incl history of recurrent & severe or protracted sinopulmonary infections & comorbid atopic conditions (asthma, allergic rhinitis, or eczema)
Hearing Audiologic evalAssess for hearing loss.
Vision Ophthalmologic evalAssess for strabismus, myopia, & astigmatism.
Genitourinary Eval for cryptorchidism, hypospadias, or micropenis in malesIf present, consider referral to pediatric urologist &/or pediatric endocrinologist.
Cardiovascular Consider echocardiography.To assess for congenital heart defects
Genetic
counseling
By genetics professionals 3To obtain a pedigree & inform affected persons & their families or caregivers re nature, MOI, & implications of int22h1/int22h2-mediated Xq28 duplication syndrome to allow for informed decision making in medical care, as well as future family planning
Family support
& resources
Help connect affected person &/or their families w/other affected persons & families.Assessment of family & social structure to determine need for:

ASD = autism spectrum disorder; MOI = mode of inheritance; PT = physical therapist

1.

For psychiatric conditions (e.g., attention-deficit/hyperactivity disorder, anxiety, mood or psychotic disorders), follow the DSM-V criteria for screening and diagnosing the respective condition(s) based on age group.

2.

Through obtaining a thorough history of prior infections and vaccinations, any reactions to the latter, and history of allergic reactions (e.g., seasonal allergies)

3.

Clinical geneticist, certified genetic counselor, certified genetic nurse, genetics advanced practice provider (nurse practitioner or physician assistant)

Treatment of Manifestations

There is no cure for int22h1/int22h2-mediated Xq28 duplication. Supportive care to improve quality of life, maximize function, and reduce complications is recommended. This ideally involves multidisciplinary care by specialists in relevant fields (see Table 5).

Table 5.

Int22h1/Int22h2-Mediated Xq28 Duplication Syndrome: Treatment of Manifestations

Manifestation/ConcernTreatmentConsiderations/Other
Obesity Refer for nutritional counseling & recommend regular exercise.
Developmental delay / Intellectual disability / Neurobehavioral issues See Neurodevelopmental Delay / Intellectual Disability Management Issues.Standard treatment (e.g., SSRIs for anxiety or depression, antipsychotics for psychotic disorders, stimulants for ADHD)
Sleep disturbance For those w/insomnia, consider conservative treatment w/proper sleep hygiene practices.In more severe cases, consider melatonin supplementation after consultation w/primary care physician or sleep specialist.
Kyphoscoliosis Refer to orthopedist for standard treatment, w/ or w/o requesting add-on help from PT/OT.
Recurrent sinopulmonary infections Standard antibiotic treatment for active bacterial infections & vaccination against S pneumoniae, H influenzae, & N meningitidis
  • Referral to pulmonologist, immunologist, &/or infectious disease specialist in those w/recurrent infections
  • Chest PT & mucolytics for those w/recurrent pneumonia
  • Referral to otolaryngologist for consideration of PE tube placement in those w/recurrent otitis media
Annual vaccination against influenza virus to ↓ risk of contracting or experiencing severe infection
Asthma Standard treatment (e.g., bronchodilators, allergen exposure prevention)Consider referral to pulmonologist & pulmonary function testing for those w/severe asthma.
Allergic rhinitis Standard treatment (e.g., decongestants, antihistamines, nasal steroids, allergen exposure prevention)
Eczema Standard treatmentConsider referral to dermatologist for those w/severe eczema.
Hearing loss Hearing aids may be helpful, to be decided by otolaryngologist.Consider community hearing services through early intervention or school district.
Refractive errors
&/or strabismus
Standard treatment(s) per ophthalmologist
Undervirilization
(in males)
Standard treatment per urologistConsider referral to pediatric endocrinologist for possible hormonal therapy as appropriate.
Congenital
heart defects
Standard treatment per cardiologist
Family/
Community
  • Ensure appropriate involvement of social workers to connect affected persons &/or their families w/local resources, respite, or support.
  • Help coordinate care to manage multiple subspecialty appointments, mobility assistance or other needed medical equipment, & medications & supplies.
  • Ongoing assessment for need for palliative care involvement &/or home nursing for cases w/severe congenital malformations & severe ID
  • Consider involvement in adaptive sports or Special Olympics.

ADHD = attention-deficit/hyperactivity disorder; ID = intellectual disability; OT = occupational therapist; PE = pressure-equalizing; PT = physical therapist; SSRI = selective serotonin reuptake inhibitor

Neurodevelopmental Delay / Intellectual Disability Management Issues

The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.

Ages 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy as well as infant mental health services, special educators, and sensory impairment specialists. In the US, early intervention is a federally funded program available in all states that provides in-home services to target individual therapy needs.

Ages 3-5 years. In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on established motor, language, social, or cognitive delay. The early intervention program typically assists with this transition. Developmental preschool is center based; for children too medically unstable to attend, home-based services are provided.

All ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies (US) and to support parents in maximizing quality of life. Some issues to consider:

  • IEP services:
    • An IEP provides specially designed instruction and related services to children who qualify.
    • IEP services will be reviewed annually to determine whether any changes are needed.
    • Special education law requires that children participating in an IEP be in the least restrictive environment feasible at school and included in general education as much as possible, when and where appropriate.
    • Vision and hearing consultants should be a part of the child's IEP team to support access to academic material.
    • PT, OT, and speech services will be provided in the IEP to the extent that the need affects the child's access to academic material. Beyond that, private supportive therapies based on the affected individual's needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.
    • As a child enters the teen years, a transition plan should be discussed and incorporated in the IEP. For those receiving IEP services, the public school district is required to provide services until age 21.
  • A 504 plan (Section 504: a US federal statute that prohibits discrimination based on disability) can be considered for those who require accommodations or modifications such as front-of-class seating, assistive technology devices, classroom scribes, extra time between classes, modified assignments, and enlarged text.
  • Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a US public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.
  • Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.

Motor Dysfunction

Gross motor dysfunction

  • Physical therapy is recommended to maximize mobility and reduce the risk for later-onset orthopedic complications (e.g., scoliosis, hip dislocation).
  • Consider use of durable medical equipment and positioning devices as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).

Fine motor dysfunction. Occupational therapy is recommended for difficulty with fine motor skill deficits or abnormalities that affect adaptive functions such as feeding, grooming, dressing, and writing.

Communication issues. For individuals with deficits in expressive language, consider evaluation for alternative means of communication (e.g., augmentative and alternative communication [AAC]). An AAC evaluation can be completed by a speech therapist with expertise in the area. The evaluation will consider cognitive abilities and sensory impairments to determine the most appropriate form of communication. AAC devices can range from low-tech (such as picture exchange communication) to high-tech (such as voice-generating devices). Contrary to popular belief, AAC devices do not hinder verbal development of speech, but rather support optimal speech and language development.

Neurobehavioral/Psychiatric Concerns

Children may qualify for and benefit from interventions used in treatment of autism spectrum disorder, including applied behavior analysis (ABA). ABA therapy is targeted to the individual child's behavioral, social, and adaptive strengths and weaknesses and typically performed one on one with a board-certified behavior analyst.

Consultation with a developmental pediatrician may be helpful in guiding parents through appropriate behavior management strategies or providing prescription medications, such as medication used to treat attention-deficit/hyperactivity disorder, when necessary.

Concerns about serious aggressive, destructive, or self-mutilating behaviors can be discussed with and addressed by a child and adolescent psychiatrist.

Surveillance

To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in Table 6 are recommended.

Table 6.

Int22h1/Int22h2-Mediated Xq28 Duplication Syndrome: Recommended Surveillance

System/ConcernEvaluationFrequency
Growth Measure growth/anthropometric parameters.At each visit
Neurodevelopmental
milestones &
cognitive abilities
Monitor progress along age-expected neurodevelopmental milestones.
Reassess special educational needs.Annually in childhood & adolescence
Neurobehavioral
& psychiatric
evaluations
Conduct thorough assessment & screening for anxiety, irritability, aggression, self-injurious behaviors, attention deficits, hyperactivity, impulsivity, & sleep disturbances.At each visit
Musculoskeletal PT/OT assessment of gross & fine motor skills, mobility, & self-care skills
Orthopedics follow upAs needed for those w/contractures &/or kyphoscoliosis
Allergy/
Immunology
  • Repeat pulmonary function testing as needed in those w/moderate-to-severe asthma.
  • Assess response to prescribed medications.
As clinically indicated or per pulmonologist
Hearing Audiology evalAt least annually in infancy & childhood, or more frequently if otherwise clinically indicated
Vision Ophthalmology evalAt least annually
Family & community
support/resources
Assess family or caregiver need for social work support (e.g., palliative/respite care, home nursing, other local resources), equipment & assistive medical devices, &/or any other special disability benefits.At each visit

OT = occupational therapist; PT = physical therapist

Evaluation of Relatives at Risk

Targeted duplication analysis of apparently asymptomatic at-risk male and female relatives of an affected individual is appropriate in order to identify as early as possible those who would benefit from early intervention services. Targeted duplication analysis can be performed by quantitative PCR (qPCR), multiplex ligation-dependent probe amplification (MLPA), or interphase FISH (iFISH) to test the relatives of a proband who is known to have the int22h1/int22h2-mediated Xq28 duplication.

Note: Clinically asymptomatic children identified as having the familial duplication should be assessed and monitored regularly for neurodevelopmental delays and neurobehavioral abnormalities.

See Genetic Counseling for issues related to the testing of at-risk relatives from a genetic counseling perspective.

Therapies Under Investigation

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.

Note: There are no registered, recruiting, or ongoing clinical trials for int22h1/int22h2-mediated Xq28 duplication syndrome to date.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

Int22h1/int22h2-mediated Xq28 duplication syndrome is inherited in an X-linked manner.

Most affected individuals reported to date exhibit maternal inheritance of the duplication (65 out of 73 individuals identified to date with the syndrome). Paternal inheritance of the duplication has been reported in eight affected individuals [Billes et al 2024, Levy et al 2024].

Risk to Family Members

Parents of a male proband

  • The father of an affected male will not have the disorder nor will he be hemizygous for the int22h1/int22h2-mediated Xq28 duplication; therefore, he does not require further evaluation/testing.
  • In a family with more than one affected individual, the mother of an affected male is an obligate heterozygote. Most of the mothers of individuals reported to date with int22h1/int22h2-mediated Xq28 duplication syndrome are heterozygous for the duplication. Some heterozygous mothers exhibit manifestations of the syndrome with milder and/or fewer features compared to their affected sons.
    Note: If a woman has more than one affected child and no other affected relatives and if the duplication cannot be detected in her leukocyte DNA, she most likely has gonadal mosaicism.
  • If a male is the only affected family member (i.e., a simplex case), the mother may be heterozygous for the duplication, the affected male may have a de novo duplication (in which case the mother is not heterozygous), or the mother may have somatic/gonadal mosaicism.
  • Genomic testing capable of detecting the int22h1/int22h2-mediated Xq28 duplication is recommended for the mother of the proband to assess her genetic status and allow reliable recurrence risk assessment. Note: Testing of maternal leukocyte DNA may not detect all instances of somatic mosaicism and will not detect a duplication that is present in the gonadal (germ) cells only.

Parents of a female proband

  • A female proband may have inherited the int22h1/int22h2-mediated Xq28 duplication from either her mother or her father.
  • Alternatively, the duplication may have occurred de novo in the proband. De novo int22h1/int22h2-mediated Xq28 duplications have been reported in two female probands [Ballout et al 2020].
  • Detailed evaluation of the parents and review of the extended family history may help distinguish probands with a de novo duplication from those with an inherited duplication. Genomic testing capable of detecting the int22h1/int22h2-mediated Xq28 duplication in the mother (and possibly the father, or subsequently the father) can determine if the duplication was inherited from a heterozygous mother or hemizygous father. Note: Testing of parental leukocyte DNA may not detect all instances of somatic mosaicism and will not detect a duplication that is present in the gonadal (germ) cells only.

Sibs of a proband

  • The risk to sibs of a male proband of inheriting the duplication depends on the genetic status of the mother.
  • The risk to sibs of a female proband of inheriting the duplication depends on the genetic status of the mother and the father.
  • If the mother is heterozygous for the int22h1/int22h2-mediated Xq28 duplication, the chance of transmission of the duplication is 50% in each pregnancy.
    • Most males reported to date with the int22h1/int22h2-mediated Xq28 duplication have cognitive impairment, neurobehavioral abnormalities, and other features associated with the syndrome (see Table 2). However, several hemizygous adult males with no discernable cognitive or neurobehavioral manifestations have been reported, suggesting that the duplication may display reduced penetrance with respect to cognition and neurobehaviors [Billes et al 2024, Levy et al 2024].
    • Females with the int22h1/int22h2-mediated Xq28 duplication may have no discernable features or may have a milder phenotype compared to affected males (see Table 3). A small subset of heterozygous females have been reported with findings that almost mirror those seen in affected males [Billes et al 2024].
  • If the father of the proband is hemizygous for the int22h1/int22h2-mediated Xq28 duplication, he will transmit it to all his daughters and none of his sons.
  • If the proband represents a simplex case and the int22h1/int22h2-mediated Xq28 duplication cannot be detected in the leukocyte DNA of the mother (or the mother and father if the proband is female), the risk to sibs of inheriting the duplication is low but greater than that of the general population due to the possibility of parental gonadal mosaicism.

Offspring of a proband

  • Hemizygous males transmit the int22h1/int22h2-mediated Xq28 duplication to all of their daughters and none of their sons.
  • Heterozygous females have a 50% chance of transmitting the duplication to offspring in each pregnancy.

Other family members. The risk that other family members have the int22h1/int22h2-mediated Xq28 duplication depends on the genetic status of the proband's parents:

Note: Genomic testing capable of detecting the int22h1/int22h2-mediated Xq28 duplication in the proband can help identify the family member in whom a de novo duplication occurred. Such information can help to determine the genetic risk of extended family members.

Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

Family planning

  • The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
  • It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who have the int22h1/int22h2-mediated Xq28 duplication.

Prenatal Testing and Preimplantation Genetic Testing

Once the int22h1/int22h2-mediated Xq28 duplication has been identified in an affected family member, prenatal and preimplantation genetic testing for a pregnancy at increased risk are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal and preimplantation genetic testing. While most health care professionals would consider use of prenatal and preimplantation genetic testing to be a personal decision, discussion of these issues may be helpful.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

  • Chromosome Disorder Outreach Inc.
    Phone: 561-395-4252
    Email: info@chromodisorder.org
  • Unique: Understanding Rare Chromosome and Gene Disorders
    United Kingdom
    Phone: +44 (0) 1883 723356
    Email: info@rarechromo.org

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A.

Xq28 Duplication Syndrome, Int22h1/Int22h2 Mediated: Genes and Databases

Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.

Table B.

OMIM Entries for Xq28 Duplication Syndrome, Int22h1/Int22h2 Mediated (View All in OMIM)

300138CHLORIDE INTRACELLULAR CHANNEL 2; CLIC2
300774RAB39B, MEMBER RAS ONCOGENE FAMILY; RAB39B
300815CHROMOSOME Xq28 DUPLICATION SYNDROME

Molecular Pathogenesis

The int22h1/int22h2-mediated Xq28 duplication breakpoints are located at the directly oriented low copy repeats (LCRs): int22h1 (located within intron 22 of F8) and int22h2 (situated ~0.5 Mb telomerically to int22h1). The duplication is mediated by nonallelic homologous recombination between the int22h1 and int22h2 loci [El-Hattab et al 2011].

It is worth noting that a third homologous region, int22h3, is located 0.6 Mb telomeric to int22h1, or about 0.1 Mb telomeric to int22h2. Ballout et al [2020] reported a heterozygous female and her affected brother with an atypical and telomerically shifted version of the int22h1/int22h2-mediated Xq28 duplication (cases 4 and 5), in which the distal breakpoint falls within the int22h3 region, rather than int22h2. Interestingly, both reported individuals exhibited features consistent with and resembling those seen in individuals with int22h1/int22h2-mediated Xq28 duplication syndrome [Ballout et al 2020].

Genomic inversions between int22h1 and either int22h2 or int22h3 are known to disrupt F8 in nearly half of individuals with severe hemophilia A [Bagnall et al 2005]. However, the int22h1/int22h2-mediated Xq28 duplication does not result in hemophilia A because the complete copy of F8 is preserved after formation of this duplication [El-Hattab et al 2011].

Genes of interest in this region. The 0.5-Mb duplicated region between int22h1 and int22h2 includes several genes. However, the intellectual disability reported in individuals with int22h1/int22h2-mediated Xq28 duplication syndrome has been hypothesized to be due to increased dosages of two genes in particular: RAB39B and CLIC2 [Andersen et al 2014, El-Hattab et al 2015].

  • CLIC2 encodes chloride intracellular channel protein 2 (CLIC2), present in cardiac and skeletal muscle cells, where it functions as a regulator of calcium release via ryanodine receptor 2 (RyR2) [Board et al 2004, Meng et al 2009]. A missense pathogenic variant in CLIC2 has been reported to be associated with a distinct form of X-linked intellectual disability syndrome in two brothers with intellectual disability, cardiomegaly, atrial fibrillation, heart failure, and seizures [Takano et al 2012]. Additionally, CLIC2 has been suggested to play a key role as a tumor suppressor, with multiple studies demonstrating that decreased CLIC2 levels associate with a more invasive phenotype of certain malignancies [Ueno et al 2019, Ozaki et al 2021].
  • RAB39B encodes a specific member of the Rab family of GTPases, Ras-related protein Rab-39B (RAB39B), that is highly expressed in central nervous system neurons, particularly in the hippocampus, where it has been shown to play a key role in the trafficking of an AMPA glutamate receptor (GluA2) and facilitating synaptogenesis and neuronal branching [Ng & Tang 2008, Mignogna et al 2015].
    Loss-of-function pathogenic variants in RAB39B have been associated with intellectual disability, autism spectrum disorders, epilepsy, impaired motor coordination, and/or microcephaly in individuals in several reported families [Giannandrea et al 2010, Mignogna et al 2022]. Loss-of-function pathogenic variants in RAB39B have also been associated with early-onset Parkinson disease [Wilson et al 2014, Lesage et al 2015].
    In contrast, increased dosages of RAB39B have been reported in four males to be associated with intellectual disability and neurobehavioral abnormalities [Vanmarsenille et al 2014]. Overexpression of Rab39b has been studied in two animal models, mice and C elegans, both of which exhibited impaired motor coordination with stereotypy and autism-like behaviors [Wang et al 2023, Zeng et al 2024]. Overexpression of Rab39b in mouse primary hippocampal neurons has been shown to result in decreased neuronal branching and total number of synapses, suggesting that increased dosages of RAB39B disrupt neuronal branching [Vanmarsenille et al 2014].

Chapter Notes

Author Notes

Rami A Ballout, MD, is a clinical fellow in Medical Genetics and Genomics at the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH). He is interested in pursuing further specialized training in clinical biochemical genetics, with a special emphasis on cholesterol biosynthesis disorders. Dr Ballout is interested in hearing from clinicians treating families affected by Int22h1/Int22h2-mediated Xq28 duplication syndrome about any unusual features or manifestations that have not been listed in the chapter and/or late-onset findings.

Christian P Schaaf, MD, PhD, is director and chairman of the Institute of Human Genetics at Heidelberg University (Germany). He specializes in the genetics of intellectual disability and autism spectrum disorder.

Acknowledgments

We wish to thank all the patients and their families/caregivers and overseeing physicians, without whom none of the original studies cited in this chapter would have been conducted.

Revision History

  • 4 September 2025 (ma) Comprehensive update posted live
  • 25 February 2021 (ma) Comprehensive update posted live
  • 10 March 2016 (bp) Review posted live
  • 31 July 2015 (aweh) Original submission

References

Literature Cited

  • Andersen EF, Baldwin EE, Ellingwood S, Smith R, Lamb AN. Xq28 duplication overlapping the int22h-1/int22h-2 region and including RAB39B and CLIC2 in a family with intellectual and developmental disability. Am J Med Genet A. 2014;164A:1795-801. [PubMed: 24700761]
  • Bagnall RD, Giannelli F, Green PM. Polymorphism and hemophilia A causing inversions in distal Xq28: a complex picture. J Thromb Haemost. 2005;3:2598-9. [PubMed: 16241967]
  • Ballout RA, Dickerson C, Wick MJ, Al-Sweel N, Openshaw AS, Srivastava S, Swanson LC, Bramswig NC, Kuechler A, Hong B, Fleming LR, Curry K, Robertson SP, Andersen EF, El-Hattab AW. Int22h1/Int22h2-mediated Xq28 duplication syndrome: de novo duplications, prenatal diagnoses, and additional phenotypic features. Hum Mutat. 2020;41:1238-49. [PMC free article: PMC7292747] [PubMed: 32112660]
  • Bastos PAD, Barbosa R. A newly identified int22h1/int22h2-mediated Xq28 duplication syndrome case misdiagnosed as cerebral palsy. Journal of Pediatric Neurology. 2022;21:360-4.
  • Billes A, Pujalte M, Jedraszak G, Amsallem D, Boudry-Labis E, Boute O, Bouquillon S, Brischoux-Boucher E, Callier P, Coutton C, Denizet A-LA, Dieterich K, Kuentz P, Lespinasse J, Mazel B, Morin G, Amram F, Pennamen P, Rio M, Piard J, Putoux A, Rama M, Roze-Guillaumey V, Schluth-Bolard C, Till M, Trouvé C, Vieville G, Rooryck C, Sanlaville D, Chatron N. Possible incomplete penetrance of Xq28 int22h-1/int22h-2 duplication. Clin Genet. 2024;106:234-46. [PubMed: 38561231]
  • Board PG, Coggan M, Watson S, Gage PW, Dulhunty AF. CLIC-2 modulates cardiac ryanodine receptor Ca2+ release channels. Int J Biochem Cell Biol. 2004;36:1599-612. [PubMed: 15147738]
  • Caughey AB, Krist AH, Wolff TA, Barry MJ, Henderson JT, Owens DK, Davidson KW, Simon MA, Mangione CM. USPSTF approach to addressing sex and gender when making recommendations for clinical preventive services. JAMA. 2021;326:1953-61. [PubMed: 34694343]
  • Chien YC, Chen JS, Shiao YM, Hsiao CH. Prenatal diagnosis of de novo int22h1/int22h2-mediated Xq28 duplication syndrome involving RAB39B following a previous ambiguous genitalia pregnancy. Taiwan J Obstet Gynecol. 2022;61:501-3. [PubMed: 35595445]
  • El-Hattab AW, Fang P, Jin W, Hughes JR, Gibson JB, Patel GS, Grange DK, Manwaring LP, Patel A, Stankiewicz P, Cheung SW. Int22h-1/int22h-2-mediated Xq28 rearrangements: intellectual disability associated with duplications and in utero male lethality with deletions. J Med Genet. 2011;48:840-50. [PubMed: 21984752]
  • El-Hattab AW, Schaaf CP, Fang P, Roeder E, Kimonis VE, Church JA, Patel A, Cheung SW. Clinical characterization of int22h1/int22h2-mediated Xq28 duplication/deletion: new cases and literature review. BMC Med Genet. 2015;16:12. [PMC free article: PMC4422130] [PubMed: 25927380]
  • Giannandrea M, Bianchi V, Mignogna ML, Sirri A, Carrabino S, D'Elia E, Vecellio M, Russo S, Cogliati F, Larizza L, Ropers HH, Tzschach A, Kalscheuer V, Oehl-Jaschkowitz B, Skinner C, Schwartz CE, Gecz J, Van Esch H, Raynaud M, Chelly J, de Brouwer AP, Toniolo D, D'Adamo P. Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly. Am J Hum Genet. 2010;86:185-95. [PMC free article: PMC2820185] [PubMed: 20159109]
  • Lannoy N, Grisart B, Eeckhoudt S, Verellen-Dumoulin C, Lambert C, Vikkula M, Hermans C. Intron 22 homologous regions are implicated in exons 1-22 duplications of the F8 gene. Eur J Hum Genet. 2013;21:970-6. [PMC free article: PMC3746252] [PubMed: 23299923]
  • Lesage S, Bras J, Cormier-Dequaire F, Condroyer C, Nicolas A, Darwent L, Guerreiro R, Majounie E, Federoff M, Heutink P, Wood NW, Gasser T, Hardy J, Tison F, Singleton A, Brice A. Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson disease. Neurol Genet. 2015;1:e9. [PMC free article: PMC4821081] [PubMed: 27066548]
  • Levy M, Elron E, Shohat M, Lifshitz S, Kahana S, Shani H, Grossman A, Amar S, Narkis G, Sagi-Dain L, Basel-Salmon L, Maya I. Exploring inheritance, and clinical penetrance of distal Xq28 duplication syndrome: insights from 47 new unpublished cases. J Hum Genet. 2024;69:337-43. [PMC free article: PMC11199134] [PubMed: 38632380]
  • Manickam K, McClain MR, Demmer LA, Biswas S, Kearney HM, Malinowski J, Massingham LJ, Miller D, Yu TW, Hisama FM; ACMG Board of Directors. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23:2029-37. [PubMed: 34211152]
  • Meng X, Wang G, Viero C, Wang Q, Mi W, Su XD, Wagenknecht T, Williams AJ, Liu Z, Yin CC. CLIC2-RyR1 interaction and structural characterization by cryo-electron microscopy. J Mol Biol. 2009;387:320-34. [PMC free article: PMC2667806] [PubMed: 19356589]
  • Mignogna ML, Ficarella R, Gelmini S, Marzulli L, Ponzi E, Gabellone A, Peschechera A, Alessio M, Margari L, Gentile M, D’Adamo P. Clinical characterization of a novel RAB39B nonstop mutation in a family with ASD and severe ID causing RAB39B downregulation and study of a Rab39b knock down mouse model. Hum Mol Genet. 2022;31:1389-406. [PMC free article: PMC9071400] [PubMed: 34761259]
  • Mignogna ML, Giannandrea M, Gurgone A, Fanelli F, Raimondi F, Mapelli L, Bassani S, Fang H, Van Anken E, Alessio M, Passafaro M, Gatti S, Esteban JA, Huganir R, D'Adamo P. The intellectual disability protein RAB39B selectively regulates GluA2 trafficking to determine synaptic AMPAR composition. Nat Commun. 2015;6:6504. [PMC free article: PMC4383008] [PubMed: 25784538]
  • Ng EL, Tang BL. Rab GTPases and their roles in brain neurons and glia. Brain Res Rev. 2008;58:236-46. [PubMed: 18485483]
  • Ozaki S, Umakoshi A, Yano H, Ohsumi S, Sumida Y, Hayase E, Usa E, Islam A, Choudhury ME, Nishi Y, Yamashita D, Ohtsuka Y, Nishikawa M, Inoue A, Suehiro S, Kuwabara J, Watanabe H, Takada Y, Watanabe Y, Nakano I, Kunieda T, Tanaka J. Chloride intracellular channel protein 2 is secreted and inhibits MMP14 activity, while preventing tumor cell invasion and metastasis. Neoplasia. 2021;23:754-65. [PMC free article: PMC8260957] [PubMed: 34229297]
  • Rodan LH, Stoler J, Chen E, Geleske T; Council on Genetics. Genetic evaluation of the child with intellectual disability or global developmental delay: clinical report. Pediatrics. 2025;156:e2025072219. [PubMed: 40545261]
  • Takano K, Liu D, Tarpey P, Gallant E, Lam A, Witham S, Alexov E, Chaubey A, Stevenson RE, Schwartz CE, Board PG, Dulhunty AF. An X-linked channelopathy with cardiomegaly due to a CLIC2 mutation enhancing ryanodine receptor channel activity. Hum Mol Genet. 2012;21:4497-507. [PMC free article: PMC3459470] [PubMed: 22814392]
  • Ueno Y, Ozaki S, Umakoshi A, Yano H, Choudhury ME, Abe N, Sumida Y, Kuwabara J, Uchida R, Islam A, Ogawa K, Ishimaru K, Yorozuya T, Kunieda T, Watanabe Y, Takada Y, Tanaka J. Chloride intracellular channel protein 2 in cancer and non-cancer human tissues: relationship with tight junctions. Tissue Barriers. 2019;7:1593775. [PMC free article: PMC6592591] [PubMed: 30929599]
  • Vanmarsenille L, Giannandrea M, Fieremans N, Verbeeck J, Belet S, Raynaud M, Vogels A, Männik K, Õunap K, Jacqueline V, Briault S, Van Esch H, D'Adamo P, Froyen G. Increased dosage of RAB39B affects neuronal development and could explain the cognitive impairment in male patients with distal Xq28 copy number gains. Hum Mutat. 2014;35:377-83. [PubMed: 24357492]
  • Wang Z, Niu M, Zheng N, Meng J, Jiang Y, Yang D, Yao P, Yao T, Luo H, Xu H, Ge Y, Zhang YW, Zhang X. Increased level of RAB39B leads to neuronal dysfunction and behavioural changes in mice. J Cell Mol Med. 2023;27:1214-26. [PMC free article: PMC10148058] [PubMed: 36977207]
  • Wilson GR, Sim JC, McLean C, Giannandrea M, Galea CA, Riseley JR, Stephenson SE, Fitzpatrick E, Haas SA, Pope K, Hogan KJ, Gregg RG, Bromhead CJ, Wargowski DS, Lawrence CH, James PA, Churchyard A, Gao Y, Phelan DG, Gillies G, Salce N, Stanford L, Marsh AP, Mignogna ML, Hayflick SJ, Leventer RJ, Delatycki MB, Mellick GD, Kalscheuer VM, D'Adamo P, Bahlo M, Amor DJ, Lockhart PJ. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology. Am J Hum Genet. 2014;95:729-35. [PMC free article: PMC4259921] [PubMed: 25434005]
  • Zeng Y, Wu T, Liang F, Long S, Guo W, Huang Y, Pei Z. Expression of human Ras-related protein Rab39B variant T168K in Caenorhabditis elegans leads to motor dysfunction and dopaminergic neuron degeneration. Heliyon. 2024;10:e26902. [PMC free article: PMC10912484] [PubMed: 38444482]
Copyright © 1993-2025, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2025 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

Bookshelf ID: NBK349624PMID: 26962617

Views

Tests in GTR by Gene

Related information

  • OMIM
    Related OMIM records
  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed
  • Gene
    Locus Links

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...